Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2000

View Archived Issues

Penwest successfully completes phase II trials of controlled-release oxymorphone

Pharmacopeia achieves second milestone in collaboration with Schering-Plough

3-D and BMS modify drug discovery alliance

Reformulated sampatrilat shows improved bioavailability in animal model

GlycoDesign and NRC establish infectious disease research program

Genta's anti-androgen compounds inhibit prostate cancer

Sumitomo licenses class of DACH platinum compounds to Aronex

Arena's CART-derived 5-HT2A receptor inverse agonists protected by several patents

Schering AG's Mirena approved by FDA

Vernalis expands frovatriptan collaboration with Elan; company to buy out royalties from SB

XTL Biopharmaceuticals updates hepatitis programs

EMEA warns of reports of tuberculosis in patients treated with Remicade

Corixa/Coulter merger complete

Lion Bioscience to acquire Trega Biosciences in 2001

Neurocrine Biosciences' CRF1 and CRF antagonists move towards clinical evaluation

Abgenix's ABX-IL-8 enters phase II evaluation for rheumatoid arthritis

Gilead's NX-211 enters phase II for second cancer indication

NDA submitted to FDA for rapidly disintegrating desloratadine tablets

Glaxo Wellcome receives E.U. approval for Seretide MDI for the treatment of asthma

Mitsubishi Chemical reveals unique compound with potential for treatment of inflammatory disorders

Chemokine receptor antagonists claimed by Takeda

PDE4 inhibitors from Merck Frosst

Compounds active against Plasmodium and cancer cells revealed by ANU

Glucagon antagonists jointly claimed by Novo Nordisk and Agouron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...